Arecoline hydrobromide treatment reduced insoluble ZO-1 levels in TM4 cells compared with mock control. In cells expressing HS α4β2 receptors, a design using Arecoline and including ACh and atropine showed reduced responses to a control application of ACh relative to initial control responses to ACh. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Insoluble junctional protein levels in cells
Cell-based study · TM4 cells [1]
TM4 cells received Arecoline hydrobromide at 200 and 400 μM for 6 hours. Insoluble ZO-1 levels fell to 74.7 ± 7.2% and 42.5 ± 10.7%, respectively, compared with mock control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 200 and 400 μM
- Exposure duration
- 6 hours
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Arecoline hydrobromide; Compound label in the paper: Arecoline
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Arecoline induces redistribution of ZO-1 directly (S37, S48); Figure 1 legend (S101, S108)
Signals of insoluble ZO-1 were quantified by densitometry analysis: Signals of insoluble ZO-1 were quantified by densitometry analysis; comparator: mock control — Results > Arecoline induces redistribution of ZO-1 directly (S48); Figure 1 legend (S108)
Control ACh responses in receptor-expressing cells
Cell-based study · cells expressing HS α4β2 receptors [2]
Cells expressing HS α4β2 receptors received Arecoline at 3 μM under steady flow in a design also including ACh and atropine. After 8 minutes, responses to a control application of ACh were reduced approximately 50% relative to initial control responses to ACh.
Literature-Reported Treatment Conditions
- Treatment concentration
- 3 μM
- Exposure duration
- After 8 minutes
- Method
- a steady flow
- Vehicle
- Ringer's solution
- Co-treatment
- Other interventions in this design: ACh 30 μM; atropine 1 μM. Compound effect isolated by the comparison: initial control responses to ACh.
Methods and source locations
Compound reported in the paper: Arecoline
The paper names Arecoline without stating the salt or form; not verified as the hydrobromide form supplied as A11815. No dose conversion or lot validation.
Materials and Methods > Commercial reagents (S3); Materials and Methods > Two-electrode voltage clamp electrophysiology (S25, S31); Results (S82); Fig 8 legend (S124, S125)
responses to a control application of ACh: responses to a control application of ACh; comparator: initial control responses to ACh — Fig 8 legend (S125)